#Breaking: @US_FDA accepted our supplemental Biologics License Application (sBLA) and granted Priority Review for an investigational adjuvant combination regimen in a certain type of stage III colon cancer: gene.com/media/press-re…
00:00
Genentech
7,805 posts
Genentech
@genentech
Official Twitter for Genentech. See our community guidelines here: ow.ly/1sSw30lmszz
- #Breaking: @US_FDA accepted the New Drug Application, under Priority Review, for our investigational oral selective estrogen receptor degrader (SERD) as a treatment for adults with ER+, HER2-, early-stage breast cancer. Learn more: gene.com/media/press-re…
00:00 - #Breaking: We are presenting data at the upcoming #ADASciSessions from our obesity portfolio, highlighting our differentiated approaches to addressing unmet needs for people living with #obesity. Learn more: gene.com/media/press-re…
00:00 - #Breaking: We’re presenting new data across breast, lung, gastrointestinal, bladder and blood cancers at the American Society of Clinical Oncology (#ASCO26). Learn more about our efforts to transform cancer care: gene.com/media/press-re…
00:00 - #Breaking: @US_FDA approved our immunotherapy as an adjuvant treatment option for adults with muscle-invasive bladder cancer (#MIBC) after surgery (cystectomy) who have circulating tumor DNA (ctDNA) molecular residual disease. Learn more: gene.com/media/press-re…
00:00 - At the Association for Research in Vision and Ophthalmology Annual Meeting, we’re sharing key real-world, product and pipeline data from our ophthalmology portfolio. Learn more: gene.com/media/press-re… #ARVO2026
- Launching today, All Eyes on DME is our new campaign highlighting diabetic macular edema (DME), an often overlooked eye condition linked to diabetes. Learn more: gene.com/media/press-re…
00:00 - #Breaking: At #AANAM, we announced positive results from our Phase III study in myelin oligodendrocyte glycoprotein antibody disease (MOGAD). Learn more: gene.com/media/press-re…
00:00- #Breaking: Today meaningful data from our Phase III study in systemic lupus erythematosus was published in @NEJM. Learn more: gene.com/media/press-re…
00:00 - #Breaking: Positive Phase II results for our investigational long‑acting amylin analog with Zealand Pharma mark an important step forward as we move from a one‑size‑fits‑all approach to more tailored options for people living with #obesity. gene.com/media/press-re…
00:00 - #Breaking: Today we announced positive additional Phase III clinical results of our investigational BTK inhibitor in people living with relapsing multiple sclerosis (RMS). Learn more: gene.com/media/press-re…
